RELATIVITY-123 MSS CRC unlikely to reach primary endpoint and will be discontinued

Other trials evaluating fixed-dose combinations of nivolumab and leratorimab as treatments for other tumor types will continue. The phase 3 RELATIVITY-123 trial (NCT05328908) tested nivolumab (Opdivo) and relatlimab (Opdurag) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who had disease progression after 1 to 4 days. ) is evaluating the effectiveness of combination […]

BMS’s Opdivo meets co-primary endpoint in colorectal cancer trial

Despite Opdivo’s success in combination trials, Bristol-Myers Squibb faces challenges as Opdivo’s European and U.S. patents expire in 2026 and 2028, respectively, threatening sales growth. There is. Credit: Dennis Diatel, via ShutterStock. Bristol-Myers Squibb (BMS) announced that its Phase III CheckMate-8HW study of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of metastatic […]